Xenon Pharmaceuticals Inc. (XENE)
After hours:
| Previous close | 30.42 |
| Open | 30.27 |
| Bid | 28.01 x 1800 |
| Ask | 32.68 x 800 |
| Day's range | 29.92 - 30.97 |
| 52-week range | 14.65 - 36.42 |
| Volume | |
| Avg. volume | 550,053 |
| Market cap | 1.635B |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 45.67 |
- GlobeNewswire
Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. The common shares were offered at a public offering price of $
- Simply Wall St.
Xenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over the last five years
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
- GlobeNewswire
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 327,868 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $30.50 per common share and t
